8月 2026
- 首頁
- Lovelace Biomedical
8月 2026Lovelace Biomedical的市場佔有率分析
Lovelace Biomedical’s expansive campus enables us to carry out sensitive projects in Albuquerque, New Mexico. Learn more here.
Lovelace Biomedical(包含公司地區)
查看更多網站流量與參與度資訊- lovelacebiomedical.org
Lovelace Biomedical截至 8月 2026 的總收入為 100M - 200M
Lovelace Biomedical 熱門網域產生的總收入
Lovelace Biomedical 熱門網域 3 年內的總收入
Lovelace Biomedical 熱門網域的總收入
Lovelace Biomedical的熱門網域總造訪量
了解Lovelace Biomedical市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
Lovelace Biomedical的熱門網域平均造訪時長
分析Lovelace Biomedical參與度指標。
過去 3 個月平均造訪時長
子公司細目
Lovelace Biomedical的熱門網域平均頁面瀏覽量
了解Lovelace Biomedical如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Lovelace Biomedical
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Toma left Lovelace Biomedical as Executive Vice President, Chief Operating Officer, and Chief Financial Officer on Jun 29th '26.Toma joins MRIGlobal from Lovelace Biomedical Research Institute, where she served as Executive Vice President, Chief Operating Officer, and Chief Financial Officer.
6月 29, 2026閱讀更多
新聞Lovelace Biomedical hired Andrew Alexander as Senior Director of Preclinical Toxicology on Jan 1st '26.[Albuquerque, N.M. - 2/5/2026] - Lovelace Biomedical, a not-for-profit preclinical contract research organization (CRO) that helps pharma, biotech, and federal partners generate the early-stage data required to advance therapies toward clinical testing, has appointed Andrew Alexander, DVM, PhD, MBA, DABT, Senior Director of Preclinical Toxicology.
2月 6, 2026閱讀更多
新聞New York Medical College partnered with Lovelace Biomedical on Jul 6th '22.To further enhance their research capabilities, NYMC, a member of TU, formed an affiliation with Lovelace last year.
7月 5, 2023閱讀更多
查看所有Lovelace Biomedical信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
